Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Exelixis Stock Price (Quote) NASDAQ:EXEL
$21.50 ( 0.89% ) Tuesday, 19th Oct 2021
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $19.62 | $22.08 | Tuesday, 19th Oct 2021 EXEL stock ended at $21.50. This is 0.89% more than the trading day before Monday, 18th Oct 2021. During the day the stock fluctuated 1.59% from a day low at $21.37 to a day high of $21.71. |
| 90 days | $16.19 | $22.08 | |
| 52 weeks | $16.19 | $25.77 |
Historical Exelixis prices
| Date | Open | High | Low | Close | Volume |
| 2021-10-19 | $21.46 | $21.71 | $21.37 | $21.50 | 755 367 |
| 2021-10-18 | $21.65 | $21.73 | $21.19 | $21.31 | 1 438 039 |
| 2021-10-15 | $22.00 | $22.08 | $21.67 | $21.82 | 3 196 844 |
| 2021-10-14 | $21.65 | $21.86 | $21.30 | $21.84 | 1 146 278 |
| 2021-10-13 | $21.40 | $21.49 | $21.02 | $21.45 | 1 134 563 |
| 2021-10-12 | $21.70 | $22.00 | $21.39 | $21.40 | 1 331 153 |
| 2021-10-11 | $21.66 | $21.86 | $21.51 | $21.67 | 959 911 |
| 2021-10-08 | $21.50 | $21.82 | $21.30 | $21.62 | 1 755 092 |
| 2021-10-07 | $21.14 | $21.57 | $20.98 | $21.56 | 1 967 311 |
| 2021-10-06 | $20.66 | $21.00 | $20.55 | $20.90 | 1 603 267 |
| 2021-10-05 | $21.16 | $21.30 | $20.88 | $20.91 | 1 434 492 |
| 2021-10-04 | $21.46 | $21.53 | $20.80 | $21.04 | 1 838 205 |
| 2021-10-01 | $21.12 | $21.74 | $20.98 | $21.54 | 1 825 688 |
| 2021-09-30 | $20.78 | $21.43 | $20.67 | $21.14 | 2 343 416 |
| 2021-09-29 | $20.68 | $20.94 | $20.47 | $20.63 | 1 841 127 |
| 2021-09-28 | $20.54 | $20.92 | $20.44 | $20.60 | 1 277 090 |
| 2021-09-27 | $20.42 | $20.78 | $20.22 | $20.70 | 1 205 934 |
| 2021-09-24 | $20.37 | $20.49 | $20.19 | $20.35 | 913 311 |
| 2021-09-23 | $20.32 | $20.53 | $20.26 | $20.50 | 1 177 123 |
| 2021-09-22 | $20.33 | $20.48 | $20.05 | $20.20 | 991 474 |
| 2021-09-21 | $19.88 | $20.42 | $19.88 | $20.33 | 1 204 624 |
| 2021-09-20 | $20.08 | $20.35 | $19.62 | $19.82 | 2 335 869 |
| 2021-09-17 | $20.45 | $20.75 | $19.96 | $20.72 | 3 837 157 |
| 2021-09-16 | $20.47 | $20.64 | $20.11 | $20.54 | 1 125 112 |
| 2021-09-15 | $20.09 | $20.63 | $20.00 | $20.47 | 1 288 958 |
| 2021-09-14 | $20.30 | $20.49 | $20.05 | $20.13 | 916 324 |
| 2021-09-13 | $20.00 | $20.60 | $19.91 | $20.22 | 1 970 463 |
| 2021-09-10 | $19.63 | $20.02 | $19.46 | $19.96 | 1 744 038 |
| 2021-09-09 | $19.80 | $20.00 | $19.50 | $19.54 | 1 384 764 |
| 2021-09-08 | $19.50 | $19.96 | $19.28 | $19.88 | 1 302 855 |
| 2021-09-07 | $19.70 | $20.09 | $19.41 | $19.52 | 2 148 141 |
| 2021-09-03 | $20.22 | $20.38 | $19.71 | $19.77 | 3 601 620 |
| 2021-09-02 | $19.64 | $20.35 | $19.51 | $20.27 | 2 572 415 |
| 2021-09-01 | $19.25 | $19.79 | $19.14 | $19.54 | 3 481 066 |
| 2021-08-31 | $19.26 | $19.50 | $19.10 | $19.17 | 1 806 743 |
| 2021-08-30 | $19.44 | $19.63 | $19.23 | $19.26 | 1 561 244 |
| 2021-08-27 | $19.20 | $19.81 | $19.15 | $19.43 | 2 054 943 |
| 2021-08-26 | $19.00 | $19.50 | $18.96 | $19.04 | 1 937 091 |
| 2021-08-25 | $18.86 | $19.28 | $18.77 | $18.91 | 1 427 253 |
| 2021-08-24 | $18.84 | $18.99 | $18.66 | $18.93 | 1 346 082 |
| 2021-08-23 | $18.60 | $19.00 | $18.55 | $18.79 | 1 456 880 |
| 2021-08-20 | $17.86 | $18.45 | $17.80 | $18.44 | 1 386 229 |
| 2021-08-19 | $18.19 | $18.40 | $17.74 | $17.79 | 1 792 129 |
| 2021-08-18 | $19.03 | $19.03 | $18.24 | $18.26 | 1 897 378 |
| 2021-08-17 | $18.27 | $19.06 | $18.17 | $19.00 | 2 329 806 |
| 2021-08-16 | $18.30 | $18.67 | $18.21 | $18.49 | 2 220 402 |
| 2021-08-13 | $18.00 | $18.70 | $17.98 | $18.28 | 3 117 147 |
| 2021-08-12 | $17.51 | $17.98 | $17.46 | $17.97 | 2 103 581 |
| 2021-08-11 | $17.28 | $17.47 | $17.07 | $17.45 | 1 657 198 |
| 2021-08-10 | $17.58 | $17.75 | $16.97 | $17.21 | 2 513 695 |
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development pr... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
